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ABSTRACT
It is paramount to understand the epidemiology of chronic Hepatitis B to in-
form national policies on vaccination and screening/testing as well as cost-
effectiveness studies. However, information on the national (Scottish) preva-
lence of chronic Hepatitis B by ethnic group is lacking. To estimate the number
of people with chronic Hepatitis B in Scotland in 2009 by ethnicity, gender and
age, the test data from virology laboratories in the four largest cities in Scot-
land were combined with estimates of the ethnic distribution of the Scottish
population. Ethnicity in both the test data and the Scottish popula-
tion was derived using a name-based ethnicity classification software
(Onomap). For 2009, we estimated 8720 (95% confidence interval: 7490 to
10230) people aged 15 and older were living with chronic hepatitis B infection
in Scotland. This corresponds to 0.2% (CI: 0.17% to 0.24%) of the Scottish
population aged 15 and older. Although East and South Asians make up a
small proportion of the Scottish population, they make up 44% of the infected
population. In addition, 75% of those infected are aged 15-44 and almost 60%
are male. This study quantifies for the first time on a national level
the burden of chronic hepatitis B infection by ethnicity, gender and
age. It confirms the importance of promoting and targeting ethnic minority
groups for hepatitis B testing.
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INTRODUCTION
Worldwide, it has been estimated that about 2 billion people have been infected
with hepatitis B virus (HBV). 240 million have chronic HBV infection (CHB)
and 600000 die each year either from CHB-associated liver cirrhosis or hepato-
cellular carcinoma [1]. A UK prevalence of 0.3% for CHB has been reported
by the Department of Health [2]. This estimate relates to data from antenatal
screening tests in the West Midlands between 1983 and 1985 [3]. More recently,
a higher prevalence of 0.45% has been predicted for England and Wales as a
result of modeling data on notifications of acute HBV [4]. Generally, higher
prevalences of CHB have been found amongst men and older people [5] and in
members of certain ethnic minority groups, especially South Asians and East
Asians [6], [7].
In the UK, universal infant or adolescent immunisation is not considered
cost-effective [8]. Instead, the joint Committee on Vaccination and Immuniza-
tion has recommended that HBV immunisation should be targeted at individuals
at high risk of HBV exposure and at people at increased risk of complications
should they acquire HBV [9].
Early diagnosis and treatment of HBV is cost-effective [10], but identifica-
tion of individuals, who are often asymptomatic, is difficult. In The Netherlands
and Canada, both countries with a low HBV prevalence [11], screening first gen-
eration migrants and early treatment of those with CHB has been shown to be
cost-effective [12], [13]. HBV testing has been part of the UK antenatal screen-
ing programme since 1998 [14]. Recent guidance from the National Institute
for Health and Clinical Excellence (NICE) recommends testing people at in-
creased risk of HBV infection. Those at higher risk are particularly migrants
from medium- or high-prevalence countries, people who inject or have injected
drugs and men who have sex with men [15].
Until now, most studies on HBV prevalence have focussed on the tested
population without comparisons made to the general population. In this study,
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we have developed an approach based on a combination of HBV laboratory test
data with estimates of the Scottish population as a means to estimate, by major
ethnic groups, the number of people living with CHB in Scotland. This approach
is of paramount importance to guide national policy and screening strategies.
Nevertheless, despite it not being a resource intensive approach, it
has not hitherto been implemented.
METHODS
Laboratory HBV test data were used to determine the prevalence of CHB by
ethnic background in (i) women undergoing an antenatal screen, and (ii) women
and men tested in other primary and secondary care settings. The former
gives information on the prevalence of CHB in females of childbearing age,
while the latter gives information on differences in the prevalence of CHB by
age and gender. To generate an estimate of the prevalence of CHB infection
among adults living in Scotland, estimates of CHB prevalence by age, gender and
ethnicity were then combined with estimates of the general Scottish population.
Laboratory data
The virology laboratories in the four largest cities in Scotland (Aberdeen, Dundee,
Edinburgh and Glasgow) provided Health Protection Scotland (HPS) with data
on all HBV-related diagnostic tests conducted at their laboratories from 1st Jan-
uary 2005 to 31st December 2009 on samples submitted from their respective
health board areas. Those areas represent approximately 60% of the Scottish
population. Information for each sample included diagnostic test results by
date, patient identifiers (including full names, date of birth, gender, postcode of
residence and the community health index (CHI) number when available [16]),
referral source of test (i.e. primary care, secondary care, antenatal and other),
and referral source/clinic number; information on ethnicity is not rou-
tinely reported with a virology test request and therefore could not
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be relied on for analysis.
Hepatitis B surface antigen (HBsAg)-positive tests and HBsAg-negative tests
were used to define infected and uninfected individuals, respectively. Indeter-
minate, weak positive or inconclusive results were excluded. In order to ensure
that HBV infection included in the study was CHB, an assessment of HBV pos-
itive individuals was performed. An HBsAg positive individual was excluded if
there was (1) a negative test within 180 days before the first positive HBsAg-
test or (2) a positive test for IgM antibodies to the hepatitis B core antigen at
the time of the first positive HBsAg-test.
Ethnicity was assigned using a name-based ‘ethnicity’ classification method-
ology (Onomap). The Onomap software classifies ethnicity based on a compar-
ison of forename and surname against a database of names sourced from public
name registries from over 26 countries. In order to correct for misclassification
in the assignment of ethnicity, predictive values from a recent validation study
of Onomap have been used [16]. This study, set in the Scottish population and
involving large datasets of birth registrations and the pupil census, concluded
that Onomap was an effective methodology for categorizing populations into a
variety of ethnic groups. When comparing predictions from Onomap to birth
registrations, the study found predictive values to determine British ethnicity
of 94.6% (positive predictive value, PPV; the proportion of people deter-
mined by Onomap to belong to a certain ethnic group which truly
belong to that ethnic group) and 74.4% (negative predictive value, NPV;
the proportion of people determined by Onomap to not belong to a
certain ethnic group which truly don’t belong to that ethnic group),
Chinese ethnicity of 70.9% PPV and 99.9% NPV and South Asian ethnicity of
53.6% PPV and 99.5% NPV. South Asian countries include Iran, Afghanistan,
Pakistan, Tibet, Nepal, India, Bangladesh, Burma and Sri Lanka. East Asian
countries include Mongolia, the People’s Republic of China, Japan, North Ko-
rea, South Korea and Taiwan. In accordance with data protection requirements,
after classification of ethnicity surnames were replaced by surname Soundex (a
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consonant-only phonetic encoding) and forenames were replaced with forename
initials. HPS Clinical Governance approval has been given for use of
names to assign ethnicity.
Records for the same person were identified using (i) a combination of fore-
name initial, soundex of surname, gender and date of birth, (ii) the CHI number,
or (iii) the referral source clinic-number. Age was calculated at the time of the
first HBsAg test. To avoid problems from a low number of tests in children un-
der the age of 15, analysis was restricted to the adult population (here regarded
as those aged 15 years or older).
HBV prevalence in women aged 15-44 years, by ethnicity
The prevalence of HBV infection in women aged 15-44 years was estimated
using test results from women living in either of the four NHS board
areas and who had been tested for HBsAg as part of the universal antenatal
screening programme. It was assumed that pregnant women tested as part
of this programme were broadly representative of all women of child-bearing
age, since very few women, about 2% in Glasgow in 2004-2009 [17], opt out of
antenatal screening.
154927 HBsAg tests on the laboratory database were recognized as antenatal
tests. Although it was not possible to identify all antenatal tests in the database,
it was assumed that misclassification in the database was non-differential.
Prevalence was stratified according to age (15-29 and 30-44 years) and ethnic
group (British and other, South Asian, East Asian and unknown). To avoid
bias from multiple testing, only the first HBsAg test for every woman during
the period 2005-2009 was used in the analysis, leaving in total 129171 tests for
analysis.
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HBV prevalence in women older than 44 years and men
older than 14 years, by ethnicity
CHB prevalence in women older than 44 years and men older than 14 years
was estimated using as a starting point the estimated prevalence generated for
women aged 15-44 years (as described above). Estimates were then adjusted
according to relative differences in prevalence for the former groups, as deter-
mined from examination of data on all men and women tested for HBsAg in
primary and secondary health care settings (excluding antenatal screens).
96763 HBsAg tests on the laboratory database had referral source identified
as either primary (29393) or secondary (67370) health care provider (excluding
tests from Genito-urinary medicine providers, occupational health services and
renal screening) and where the test was not also recognized as an antenatal
screening test. Again, only the first HBsAg test for individuals was used in
the analysis. For each ethnic group separately, Poisson regression was used
to generate relative risks of testing HBsAg-positive for (a) men compared to
women, and (b) women older than 44 years compared to those aged 15-29 years,
adjusting for NHS board and referral source. For East Asians, women aged 15-
44 were grouped together to avoid problems with small numbers in the Poisson
models. Year of test (i.e. 2005, 2006, 2007, 2008, 2009) was not a significant
confounder of HBsAg positivity and therefore was not included further in the
regression models. Similarly, no significant interaction between age and gender
was found and the interaction term was therefore not included in regression
models.
For each ethnic group, the estimated prevalence of HBsAg positivity in
women older than 44 years was calculated by multiplying the prevalence in
women aged 15-29 years (generated from the antenatal test data) with the rela-
tive risk of testing HBsAg-positive among women older than 44 years compared
to those aged 15-29 years (generated from primary and secondary health care
test data). The prevalence in men was similarly estimated, applying the relative
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risk for men compared to women. For example, to estimate the prevalence in
British men older than 44 years, the prevalence in British women, aged 15-29
years (0.16%, Table 1) was multiplied with the adjusted relative risk of British
men and women older than 44 year compared to British men and women aged
15-29 years (RR 0.3, Table 2). The resulting product (0.05%) was then multi-
plied with the adjusted relative risk of British men compared to British women
(RR 1.69, Table 2) resulting in an estimated prevalence of 0.08% (Table 4).
In estimating the ethnic-specific CHB prevalences in older women and men, it
was assumed that the relative risks, as calculated from tests conducted in pri-
mary and secondary health care settings, were representative of differences in
the general population.
Scotland’s population in 2009, by ethnicity
Names, gender and age of all people registered with a general practitioner (GP)
in Scotland in June 2011 (N=5800674 observations) were extracted from the
CHI database at Information Service Division, Scotland. The number of peo-
ple in the CHI database slightly exceeds the number of people living
in Scotland because it can include some visitors, duplicate records,
people who have moved out of Scotland (and are not known to have
moved) and people who have died in that year. The distribution of
the Scottish populations by age (15-29, 30-44 and > 44), gender and ethnicity
(British and Other, South Asian and East Asian) in 2011 was then estimated
using Onomap. To correct for misclassification in the assignment of ethnicity,
the estimated distribution was then corrected using published predicted values
[16]. Finally, corrected estimates were applied to the size of the Scottish pop-
ulation in 2009 according to age group and gender, predicted by the General
Register Office for Scotland (GRO; N=5194000 [18]). In using data from
CHI, it was assumed that ethnic minority groups are represented in
the CHI database in the same proportion as in the general popula-
tion. Estimates generated from the CHI database were compared to results
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from the latest (2001) census (N=5062000) [19], at the time of analysis,
and to published estimates for 2010 by Wohland et al. (N=4940000) [20],
who predicted the size of the Scottish population using estimates of ethnic group
fertility, ethnic group mortality, internal and international migration.
Scotland’s CHB population in 2009, by ethnicity
Scotland’s CHB population in 2009 was estimated as the product of the es-
timated CHB prevalence and the estimated size of the population in 2009 by
gender, age group and ethnicity. Confidence intervals (CI) for these estimates
were derived by replacing the following three parameters with distributions and
then repeatedly (10000 iterations) randomly sampling from those distributions:
i) the prevalence of CHB in the antenatal population, ii) the log of the ad-
justed relative risk of testing HBsAg-positive among women older than 44 years
compared to those aged 15-29 years and men compared to women and iii) the
predictive values for Onomap classification. For each ethnic group separately,
parameters were replaced with the following distributions: i) the prevalence of
CHB in the antenatal population was replaced with a binomial distribution with
n equal to the number of women tested in antenatal tests and p equal to the
proportion of n who tested positive; ii) the log of the adjusted relative risks was
replaced with a normal distribution with mean of the log of the adjusted RR
and the standard error (SE) as estimated from the Poisson models; iii) the pre-
dictive values for Onomap classification was replaced with a normal distribution
with mean and the SE as published by [16]. In generalizing results to the Scot-
tish population, it was assumed that the ethnicity, gender and age-specific CHB
prevalence estimates for the four largest Scottish NHS boards was representative
of the Scottish population.
Data processing and analysis
PostgreSQL (Version 9.0.1, PostgreSQL Global Development Group) was used
for data storage and data linkage. R statistical package (V 2.13.1, R Foundation
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Table 1: Number of women tested for HBsAg and percentage testing HBsAg-
positive at their first recorded antenatal screening between 2005 and 2009 in
Scotland.
Age group N % HBsAg+ve .% of N (95% CI)
British and other .
15-29 64397 50 103 0.16 (0.13 to 0.19)
30-44 55006 43 55 0.10 (0.08 to 0.13)
Both age groups 119403 92 158 0.13 (0.11 to 0.15)
South Asian .
15-29 3518 3 15 0.43 (0.24 to 0.70)
30-44 2117 2 18 0.85 (0.50 to 1.34)
Both age groups 5635 4 33 0.59 (0.40 to 0.82)
East Asian .
15-29 841 0.6 106 12.60 (10.44 to 15.04)
30-44 687 0.4 51 7.42 (5.58 to 9.65)
Both age groups 1528 1 157 10.27 (8.80 to 11.91)
Unknown .
15-29 1680 1 10 0.60 (0.29 to 1.09)
30-44 925 1 17 1.84 (1.07 to 2.93)
Both age groups 2605 2 27 1.04 (0.68 to 1.50)
All ethnic groups .
15-44 129171 100 375 0.29 (0.26 to 0.32)
for Statistical Computing) and @RISK (V5, Palisade Corporation) were used
for statistical analysis and modelling.
RESULTS
HBV prevalence in women aged 15-44 years, by ethnicity
375 women tested HBsAg-positive in 129171 antenatal screening tests in Scot-
land during 2005-2009 (Table 1). This corresponds to a prevalence of 0.29%
(95% CI 0.26-0.32%). The majority of women for whom an ethnic group could
be determined were of British and Other ethnicity (94%). The prevalence in
this group was 0.13%. Higher proportions of women in the South Asian (0.59%)
and East Asian (10.3%) ethnic groups were found to be HBsAg positive. Among
South Asian women, the prevalence was higher for women aged 30-44 compared
to 15-29 years, whereas among women with East Asian and British and Other
ethnicity the prevalence of HBsAg was higher for women aged 15-29.
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HBV prevalence in women older than 44 years and men
older than 14 years, by ethnicity
Compared to females of South Asian and British and Other ethnicity, males had
a 1.7 - 1.8 times higher risk of testing HBsAg-positive (Table 2). No significant
gender difference in risk was observed for East Asian ethnicity. Compared to
those aged 15-29, those aged 44 years and older of British and Other ethnicity
had a significantly lower risk of testing HBsAg-positive (RR 0.3, 95%CI 0.2 to
0.4). No significant difference in risk by age was observed for those of South and
East Asian ethnicity. Compared to women and men tested in secondary
care, those tested in primary care had a higher risk of testing positive.
This pattern was observed for all ethnic groups and age groups with
the exception of 30-44 year old East Asian females who had a similar
risk in primary and secondary care.
Multiplying the adjusted relative risk estimates for each ethnic group (Table
2) with the prevalences of HBsAg positivity in women aged 15-29 years (Table
1), estimates of the prevalence of CHB were generated (Table 4(a)). Estimates
for the prevalence of CHB in men ranged from 0.08% in those of British/Other
ethnicity aged over 44 years to 11.6% in those of East Asian ethnicity aged
15-44 years. Estimates for the prevalence of CHB in women aged over 44 years
ranged from 0.05% in those of British and Other ethnicity to 9.3% in those of
East Asian ethnicity.
Scotland’s population in 2009, by ethnicity
Through the approach of applying Onomap to the CHI database it was esti-
mated that 1.5% and 0.7% of the Scottish population aged 15 years or older in
2009 were of South Asian and East Asian ethnicity, respectively (Table 3). For
South Asians, the estimate was higher than that reported from the 2001 Sottish
Census (1.0%) and from [20] for the year 2010 (1.1%). For East Asians, it was
higher than that reported from the 2001 census (0.3%), but comparable to the
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Table 2: Relative risks of testing HBsAg-positive among men and women older
than 15 years who had been tested for HBsAg in primary and secondary care
settings (excluding all antenatal tests) in Scotland during 2005-2009, stratified
by ethnicity.
Variable Level N % HBsAg-pos % of N RR
unadjusted adjusteda
(a) British and other
Source Secondary Care 53957 68 271 0.50
Primary Care 25768 32 226 0.88 1.75 (1.46 to 2.08) 1.57 (1.31 to 1.88)
Gender Female 36546 46 166 0.45
Male 43179 54 331 0.77 1.69 (1.4 to 2.03) 1.69 (1.40 to 2.04)
Age group 15-29 15533 19 160 1.03
30-44 24359 31 219 0.90 0.87 (0.71 to 1.07) 0.83 (0.68 to 1.02)
>44 39833 50 118 0.30 0.29 (0.23 to 0.36) 0.30 (0.24 to 0.39)
NHSboard GG&Cb 30762 39 248 0.81
Other 48963 61 249 0.51 0.63 (0.53 to 0.75) 0.66 (0.55 to 0.79)
(b) South Asian
Referral Secondary Care 1431 44 30 2.10
Source Primary Care 1830 56 83 4.54 2.16 (1.43 to 3.28) 2.05 (1.34 to 3.13)
Gender Female 1159 36 25 2.16
Male 2102 64 88 4.19 1.94 (1.24 to 3.03) 1.81 (1.16 to 2.83)
Age group 15-29 1127 35 33 2.93
30-44 1287 39 50 3.89 1.33 (0.85 to 2.06) 1.25 (0.81 to 1.95)
>44 847 26 30 3.54 1.21 (0.74 to 1.98) 1.25 (0.76 to 2.06)
NHSboard GG&C 2056 63 75 3.65
Other 1205 37 38 3.15 0.86 (0.59 to 1.28) 0.95 (0.64 to 1.40)
(c) East Asian
Referral Secondary Care 503 45 101 20.08
Source Primary Care 627 55 146 23.29 1.16 (0.90 to 1.49) 1.22 (0.94 to 1.57)
Gender Female 551 49 110 19.96
Male 579 51 137 23.66 1.19 (0.92 to 1.52) 1.13 (0.88 to 1.46)
Age group 15-44 887 78 198 22.32
>44 243 22 49 20.16 0.90 (0.66 to 1.23) 0.91 (0.66 to 1.24)
NHSboard GG&C 489 43 134 27.40
Other 641 57 113 17.63 0.64 (0.50 to 0.83) 0.63 (0.49 to 0.82)
aAdjusted for Source, Gender, Age and NHS board
bGreater Glasgow & Clyde
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Table 3: Distribution (percentage) of the Scottish population by ethnicity, sex
and age group. a) CHI database (adjusted to 2009 population), b) ETHPOP
estimate for the population in 2010 and c) Census in 2001
Age group a) CHI databasea b) ETHPOP estimate c) Census
(2009) (2010) (2001)
Females Males Females Males Females Males
British and other
15-29 11.17 11.54 10.94 11.41 11.22 11.10
30-44 12.10 11.26 11.89 11.18 14.22 13.34
>44 27.87 23.85 28.52 24.29 26.59 22.26
South Asian
15-29 0.24 0.36 0.18 0.19 0.19 0.20
30-44 0.23 0.34 0.18 0.19 0.15 0.17
>44 0.15 0.20 0.17 0.19 0.11 0.13
East Asian
15-44 0.28 0.26 0.25 0.25 0.12 0.12
>44 0.07 0.08 0.10 0.09 0.04 0.04
aAdjusted for PPV and NPV of name classification using Onomap and for the predicted
size of the population.
estimate from [20](0.7%).
Scotland’s CHB population in 2009, by ethnicity
By applying the CHB prevalence estimates (Table 4a) to the estimates of the
adult Scottish population by ethnicity, gender and age group (as in Table 3a)
it was estimated that approximately 8720 (95% CI 7490-10230) people aged 15
and older infected with CHB were living in Scotland in 2009; this represents a
population prevalence among people aged 15 and older of 0.2% (95% CI 0.17-
0.24%). Of the 8720, 56% (4920, CI 3970-6050) were predicted to have British
and Other ethnicity, 37% (3200, CI 2460-4120) to have East Asian ethnicity and
7% (600 CI 360-960) to have South Asian ethnicity. 75% (6530 CI 5630-7580)




This is the first time a CHB prevalence of 0.2% for all Scotland has been pre-
dicted based on a combination of laboratory data and population demographics.
This prevalence was slightly lower than the generally accepted figure of 0.3% for
the UK population [2] and less than half of the most recent published prevalence
of 0.45% in England and Wales [4]. These differences in predictions could be
explained by differences in the ethnic composition of the Scottish population
(98% ’White’ in the 2001 census) compared to the English population (91%
’White’ in the 2001 census). Additionally, these differences may be explained
by different assumptions made about the prevalence of CHB in men compared
to women. In the study with 0.3% CHB [2] it was assumed that compared to
women, men had a two-fold higher risk, while our study indicated that gender
differences in CHB prevalence were modified by ethnicity.
Different CHB rates by ethnicity are likely caused by different
modes of transmission — gender-neutral vertical transmission in the
Chinese population and male-dominated horizontal transmission in
the British & Other group. However, the increased risk for South
Asian males compared to females of the same ethnicity were unex-
pected. Additional information on exposure risks through enhanced
surveillance with local NHS Boards — responsible for following up
new cases and contact tracing — is needed to explain these results.
Given the high prevalence of CHB in ethnic minority groups, estimates of
the ethnic composition of the general population are crucial but rarely available.
In this study we present a novel approach to estimate the proportion of East
Asians and South Asians in the Scottish population using a name-based eth-
nicity classification software applied to data on all people registered with a GP
in Scotland (CHI database). We aim to extend this to other ethnic groups (in
particular East Europeans and Africans) once data from the 2011 Scottish cen-
sus become available. Indeed, once detailed predictions of the number
14
of people living in England, Wales and Northern Ireland in 2011 by
age group, sex and ethnicity become available, the number of people
with CHB could be calculated for the whole of the UK.
Approximately 3200 CHB infected people aged 15 and over with East Asian
ethnicity were predicted to be living in Scotland in 2009, almost 40% of the total
predicted CHB-positive population. The high number of infected people was due
to the high prevalence of CHB in this population (e.g., 10% of women having had
an antenatal test), while population estimates indicated that the proportion of
adult East Asians in the Scottish population was low at 0.7%. Estimates of the
large proportion of East Asians in the CHB infected population is supported by
results from an (unpublished) Scotland-wide survey of Hepatitis B specialist
services during 2009 which showed that approximately 50% of CHB patients at
clinics were of Chinese ethnicity (G. Hawkings, personal communication).
Efforts to target the Chinese population and other ethnic minority groups
for HBV testing and immunisation are already under way in Scotland (Andrew
Bathgate, personal communication), the rest of the UK [21] and in other Eu-
ropean Countries [22], [23]. Without such initiatives to diagnose CHB infected
individuals (particularly men, as they are not covered through antenatal screen-
ing) cases go undiagnosed until symptoms develop.
Our study had several limitations. Whilst we give 95% confidence intervals
for our prevalence estimates, we could only take account of the statistical un-
certainty in the estimated prevalence of i) CHB in the antenatal population, ii)
the relative risk of testing HBsAg-positive among women older than 44 years
compared to those aged 15-29 years and men compared to women; and iii) the
predictive values for Onomap classification.
In order to estimate the prevalence of CHB in men and in women older than
44 years, it was assumed that the relative risks, as calculated from HBV tests
conducted in primary and secondary health care settings, were representative
of differences in the general population. This assumption is supported by a
comparison of CHB prevalences between women aged 15 to 29 years and those
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aged 30 to 44 years in antenatal tests and in primary and secondary care. In
antenatal tests of British and Other women, those aged 15 to 29 had a 1.6 times
higher prevalence compared to those aged 30 to 44 years. In tests taken in
primary and secondary care the rate between the two age groups was a similar
1.3. In antenatal tests of South Asian women, those aged 15 to 29 had a 0.5
times lower prevalence compared to those aged 30 to 44 years. In tests taken in
primary and secondary care the rate between the two age groups was a similar
0.8. However, it is possible that the estimated relative risks are confounded by
different indications for testing in the different age and gender strata. Reasons
for HBV testing are not routinely recorded with the laboratory surveillance data
and could therefore not be included in the analysis.
We relied on estimates for the PPV and NPV from Lakha et al. [16] to adjust
for misclassification of Onomap in generating estimates of Scotland’s population
by ethnicity in 2009. The distribution of the Scottish population derived through
this process was similar to that reported by Wohland et al. [20]. Slightly higher
estimates of the proportion of South Asian males in the latter study would have
little effect on the predicted prevalence of CHB in Scotland, a reduction by
0.008%.
In our analysis, people from low HBV prevalence countries (e.g. the UK
and Northern Europe) were grouped together with people from medium and
high prevalence countries (e.g. Eastern and Southern Europe, Africa) due to
the sub-optimal performance of Onomap to accurately classify names relating
to the latter ethnic groups [16]. The prevalence observed from antenatal tests
in the British and Other stratum (0.13%) was therefore higher than in British
women alone (0.06%) ; the observed higher prevalence in those aged 15-
29 compared to 30-44 years in the British and Other ethnicity could
be due to a higher proportion of the younger group originating from
medium and high prevalence countries.. Further work is therefore needed
to accurately predict the numbers of people with CHB within ethnic minority
groups, other than East and South Asians.
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Name-based ‘ethnicity’ classification is routinely used by Public
Health England to assign ethnicity to laboratory test data [24]. In
the absence of information on ethnic background of people tested
for CHB in various settings, use of full names was here the only
way to attribute ethnicity and calculate reliable estimates of national
prevalence. Consent to generate ethnicity data from the thousands
of individuals undergoing a HBV test was not retrospectively sought.
Permission to use personal information was however granted by HPS’
Clinical Governance Committee, as the public health gain of this
exercise far outweighed the negligible risk to the individual. Name-
based ‘ethnicity’ classification was not available for tests conducted in
sexual health clinics or occupational health in Scotland, because these
usually do not share personal identifiers without explicit permission.
In conclusion, this study has estimated that in Scotland in 2009 approxi-
mately 8700 people over the age of 14 (0.2% of this population) were infected
with CHB. Slightly less than half of the infected population belongs to eth-
nic minority groups. There is a need to identify the undiagnosed population
and thereby to prevent disease progression into liver cirrhosis and liver cancer
and to prevent spread of disease into the non-infected population. To this end,
novel strategies should be developed to promote and offer testing to people at
increased risk of CHB. Indeed, the Scottish Government’s Sexual Health
and Blood-borne Virus Framework aims to better targeted testing,
early diagnosis and effective treatment and care of blood borne virus
infections [25]. Our study has also demonstrated that even without
access to population sizes from census statistics, the size of the in-
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Calculation of the size of the Scottish population by ethnicity, sex
and age group (Table 3) — adjustments for the predictive values of
name classification using Onomap and for the predicted size of the




where a is the number of true positives and a+b is the number of test positives.




where c is the number of true negatives and c+d is the number of test negatives.
To estimate the adjusted total number of people in the CHI database that belong
to ethnic group i, we calculated
Pi = PPV ∗ (a+ b) + (1 −NPV ) ∗ (c+ d)
where Pi denotes the adjusted number, PPV ∗ (a + b) denotes the number of
people that were rightly classified by Onomap to belong to ethnic group i and
(1−NPV ) ∗ (c+ d) denotes the number of people that were wrongly classified
by the software as not belonging to ethnic group i.
Once Pi had been calculated, the size of the different age and sex strata in the
23
extract from CHI could be estimated assuming that both age and sex had been
recorded in the CHI database without misclassification and that misclassification
by Onomap was not modified by age group or sex.
As the number of people in the CHI database by age and sex does not
accurately estimate the size of the Scottish population, estimates for the latter
were extracted from GRO. People in the different age and sex strata in the
Scottish population were then assigned an ethnic group based on the (Onomap-
adjusted) distribution of ethnic groups in the CHI extract.
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